Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alpha-2b recombinant interferon (Intron-A) as maintenance treatment in multiple myeloma.
Avvisati G, Petrucci MT, Pulsoni A, Tribalto M, Lauta VM, Gernone A, Boccadoro M, Marmont F, Pileri A, Dammacco F, et al. Avvisati G, et al. Among authors: lauta vm. Eur J Haematol Suppl. 1990;52:9-11. doi: 10.1111/j.1600-0609.1990.tb00897.x. Eur J Haematol Suppl. 1990. PMID: 2279547 Clinical Trial. No abstract available.
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial.
Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M, Lauta VM, Bergonzi C, Barbui A, Caravita T, Capaldi A, Pregno P, Guglielmelli T, Grasso M, Callea V, Bertola A, Cavallo F, Falco P, Rus C, Massaia M, Mandelli F, Carella AM, Pogliani E, Liberati AM, Dammacco F, Ciccone G, Boccadoro M. Palumbo A, et al. Among authors: lauta vm. Blood. 2004 Nov 15;104(10):3052-7. doi: 10.1182/blood-2004-02-0408. Epub 2004 Jul 20. Blood. 2004. PMID: 15265788 Free article. Clinical Trial.
Conventional induction treatments do not influence overall survival in multiple myeloma.
Boccadoro M, Palumbo A, Argentino C, Dominietto A, Frieri R, Avvisati G, Comotti B, Lauta VM, Liberati M, Marmont F, Musto P, Tribalto M, Pileri A. Boccadoro M, et al. Among authors: lauta vm. Br J Haematol. 1997 Feb;96(2):333-7. doi: 10.1046/j.1365-2141.1997.d01-2041.x. Br J Haematol. 1997. PMID: 9029022 Free article.
Therapy of multiple myeloma. Italian Multiple Myeloma Study Group.
Boccadoro M, Avvisati G, Cantonetti M, Cavo-Comotti BM, Frieri R, Gallamini A, Gallone G, Lauta VM, Liberati M, Marmont F, et al. Boccadoro M, et al. Among authors: lauta vm. Pathol Biol (Paris). 1990 Oct;38(8):829. Pathol Biol (Paris). 1990. PMID: 2274374 No abstract available.
An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy.
Boccadoro M, Tarella C, Palumbo A, Argentino C, Triolo S, Dominietto A, Callea V, Lauta VM, Molica S, Musto P, Marmont F, Gianni AM, Pileri A. Boccadoro M, et al. Among authors: lauta vm. Haematologica. 1999 Oct;84(10):905-10. Haematologica. 1999. PMID: 10509038 Clinical Trial.
How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?
Zinzani PL, Martelli M, Magagnoli M, Zaja F, Storti S, Pavone E, Lauta VM, De Renzo A, Gobbi M, Bocchia M, Ronconi F, Scaramucci L, Gherlinzoni F, Palombi F, Bendandi M, Stefoni V, Anticoli Borza P, Cellini C, Mandelli F, Tura S. Zinzani PL, et al. Among authors: lauta vm. Haematologica. 1999 Nov;84(11):996-1001. Haematologica. 1999. PMID: 10553159 Clinical Trial.
37 results